Canada Markets closed

Aptose Biosciences Inc. (APS.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
1.0500-0.0100 (-0.94%)
At close: 03:59PM EDT

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Aug. 15, 2022.

Sign in to post a message.
  • D
    Daniel
    No hope.
    I sold 1,000 shares a month ago without scratch. I still have 458 shares with a little down.
  • W
    Wolverine
    So, are the two patients still on study at 900 mg the same two patients that previously showed a tumor reduction in B Cell? Or are these two new tumor reductions.
  • C
    Carol J
    Tiaraboy where are you??
  • d
    dcaf7
    Are they going to report new response(s) tomorrow?
  • T
    Thomas
    If the stock price doesn’t get up to $1.00 very soon, we’ll be heading for a reverse split.
  • T
    Tartiaboy
    Be First, be right, be patient. APTO is certainly testing this strategy.

    I have been heavily invested in APTO for several years now. This is my high level assessment of our situation.

    I believe that both Lux and 239 are very valuable assets, but that this is not recognized by the street for several reasons.

    1. APTO is being run by scientists/MD's who are taking a very scientific sequential approach with Lux and 293. They are trying to be super thorough which is taking time. Witness the time they are spending on exploring the potential of 293 as a single agent. Witness the long drawn out dosing efforts with Lux.

    I have followed the pre-clinical data for several years now and I continue to believe that the Lux data as a single agents is not unreasonable. i.e. the lack of clear ORR at the doses up to 2 microM. The IC50 scatter plots of Lux in NHL suggest that there is a population of patients that have IC50s at or above this level. I believe that the patients with IC50s above 2 microM are actually heavily skewed into the patient population that APTO is trying to address. So what the solution? Try to get to 4 or 5 microM with the G3 formulation is part of it, but I don't believe it is the real answer. What is? COMBINATIONs are the answer.

    The real value of both 239 and Lux will not be seen until APTO gets into combination studies. Only when APTO is running combinations will I be willing to assess that these drugs are successful of not.

    Our problem is that APTO is taking forever to get to that level of study.

    Be First, be right, be patient and do your DD.
  • W
    Wolverine
    Point of concern- Apto needs to partner with someone soon. If they shelve Lux, this company is going to run out options soon. Still have hope with 239, but need partner or outright sale soon. Better to sell for $4/share now than watch this bleed out over the next year.
  • d
    dcaf7
    From new Corporate presentation:
    1. Lux is barely mentioned. Looks like on the way out.
    2. No additional responses with 239.
    3. Plan to explore 40 mg dose level of 239 in dose exploration cohort. Why? Very suspicious.
    4. Slide 19 shows potential AML cohorts for future studies. Too many. Not a mutation agnostic approach.
    5. Slide 21 shows commercial potential of 239 in different patient populations. Didn't expect that FLT3(+) RR AML/Prior FLT3i (Gilt) segment is valued only as $25M opportunity.
    6. Timeline of 239 development is on slide 23. They plan to start first registrational trial in Sep 2023.
  • C
    Carol J
    I see that somebody has not done their DD. They referred to Aptose as a young biotech. There is nothing young or new about Aptose.

    Lorus Therapeutics established in the late 1980s or 90s formally change their name to Aptose in 2014. Lorus just like Aptose entered in license agreements to develope compounds all of which failed. In 2014 they changed their name to Aptose and begin working to revive LOR253/APTO253 which they had been working on since the 1990s, then they signed a 125M lease for 806, 253 was quietly terminated after over 25 years of development and money, they then signed a 425M lease for 239.
  • d
    dcaf7
    A balanced view on APTO, "Aptose Biosciences Continues To Drift Without Thesis-Changing Data".
    Cannot post a link.
  • C
    Carol J
    Why havent they announced this historical finding to the medical world that Aptose has 2 clinical trials where all subjects achieved CRs.
  • C
    Carol J
    11 Million in Qtrly Expenses 3 Million which was salaries and benefits.
  • C
    Carol J
    Tiaraboy where are, the gentlemen are waiting to hear from you. As you use to say dont be last be first and right now last is the only position left.

    Aptose is failing and cash on hand is very low for Aptose who is a big spender. Aptose is paying their officers a million dollars and a million shares despite the company is tanking and probably will be defunct by the end of the year.
  • W
    Wolverine
    Dcaf/Tartia- Any comments from our resident PHD's on the new corporate presentation?
  • C
    Carol J
    @Wolverine you have got to be kidding if you think Apto will ever reach $4 a share again that will never happen just like NO ONE IS GOING TO PARTNER WITH APTOSE!! APTOSE LIABILITIES EXCEED THEIR ASSETS. INSTEAD OF APTOSE COLLABORATING WITH CG ON 806 WHERE THEY WOULD SHARE THE RISKS AND EXPENSES OF THE CLINICAL TRIALS THEY SIGNED A LICENSE AGREEMENT TO RENT 806 FOR $125,000,000 AND ASSUME ALL RISKS AND EXPENSES.

    THE SAME WITH HAMNI FOR 239 INSTEAD OF PARTNERING WITH HAMNI AND SHARE THE RISKS AND EXPENSES THEY SIGNED A RECORD $425,000,000 LEASE AGREEMENT TO ASSUME ALL THE RISKS AND EXPENSES OF DEVELOPEMENT.

    DONT SIT AROUND WAITING FOR A WHITE KNIGHT TO COME IN AND RESCUE OR PARTNER WITH APTOSE WITH 550 MILLION IN LEASE AGREEMENTS AND 11-15 MILLION IN OPERATING COSTS PER QTR AND 3 FAILING PHASE 1 STUDIES.
  • C
    Carol J
    ASK RICE ABOUT THE 425M RENTAL AGREEMENT THEY SIGNED FOR 239. HOW MUCH HAVE THEY PAID THEM TO DATE AND WHAT IS THE TERMS AND PAYMENT FOR THIS ENORMOUS CONTRACT. THE SAME FOR THE 125M lease for 806.
  • C
    Carol J
    239 trial was ongoing for 4 years had only enrolled 12 subjects when Aptose signed a record 425MILLION DOLLAR LEASE AND ASSUME ALL RISKS AND EXPENSES FOR 239. WHY DID THEY SIGN A LEASE BUT MOST OF ALL WHY WOULD HAMNI LEASE THE COMPOUND IF IT WAS DOING SO GREAT!!
  • B
    Bob
    Carol J... is Aptose a scam?
    Give it to me straight.
  • J
    John
    I have following this board for a while and I way waiting to see who was right Tartiaboy or CarolJ and now we know. If we had of listened to her we wouldn't be sitting here with shares @0.80 and below.
  • M
    Mark
    My one good take from APTO is that they brought in this new guy from Merck, Ledu, who was in charge of the Arqule acquisition (while at Merck). I bought APTO because I read their product had a similar science behind it like Arqule's. I wonder if this guy was brought in to check APTO out for a buyout and then go back to his old job at Merck. Just trying to connect the dots with a little wishful thinking. Cheers.